17Sep/13

Health Canada approves Aastrom's clinical trial application for heart failure drug – Pharmaceutical Business Review

Health Canada approves Aastrom’s clinical trial application for heart failure drug
Pharmaceutical Business Review
Currently patients are being enrolled in the US to participate in the ixCELL-DCM trial, which is a randomized, double-blind, placebo-controlled study of ixmyelocel-T in patients with advanced heart failure due to ischemic dilated cardiomyopathy (DCM), 
Aastrom (ASTM) Approved Trial Application for P2b Study in CanadaProactive Investors USA & Canada

all 3 news articles »

17Sep/13

Multiple Sclerosis Therapeutics to 2019 – Treatment Diversification … – Sacramento Bee

Multiple Sclerosis Therapeutics to 2019 – Treatment Diversification
Sacramento Bee
40 4.5.3 Laquinimod (laquinimod sodium) – Teva Pharmaceuticals 41 4.5.4 ocrelizumab – F. Hoffman-La Roche 42 4.5.5 daclizumab – Biogen Idec and Abbot Laboratories 42 4.5.6 firategrast – GlaxoSmithKline 43 4.5.7 Siponimod (BAF-312) – Novartis AG 

and more »